Back to results
US 2023/0390293 A1Published application
Pharmaceutical compositions of ibrutinib
AssigneeCipla Limited
InventorsGeena Malhotra, Jinesh Chauhan, Kishore Kothule, Ravichandra Bhadravathi Vedamurthy, Anirban Mallik Thakur
Life of this patent
Estimating the term…
Abstract
This invention relates to novel pharmaceutical formulations of Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib. This invention also relates to methods of using the Ibrutinib pharmaceutical formulations, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, cancers, including lymphoma, and inflammatory diseases or conditions.
Claims17
1-6. (canceled)
A method of treating cancer by administering to a patient in need thereof a composition comprising:
- a) 140 mg of ibrutinib, wherein the ibrutinib is polymorphic Form C;
- b) a disintegrant in an amount from 3-30% w/w;
- c) a diluent in an amount from 15-60% w/w;
- and
- d) a lubricant in an amount from 0.1-5% w/w,
- wherein the composition does not contain a surfactant.
3 more elements
Dependencies are inferred from the claim text.